Steady-state plasma pharmacokinetics of oral voriconazole in obese adults

Antimicrobial Agents and Chemotherapy

Volumn 55, Issue 6, 2011, Pages 2601-2605

  Pai, Manjunath P ^a   Lodise, Thomas P ^a  

^a ALBANY COLLEGE OF PHARMACY AND HEALTH SCIENCES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

VORICONAZOLE;

ADULT; AREA UNDER THE CURVE; ARTICLE; BODY MASS; BODY WEIGHT; CLINICAL ARTICLE; CONTROLLED STUDY; CROSSOVER PROCEDURE; DRUG BLOOD LEVEL; FEMALE; HUMAN; LEAN BODY WEIGHT; LOADING DRUG DOSE; MALE; MAXIMUM PLASMA CONCENTRATION; OBESITY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; STEADY STATE; TIME TO MAXIMUM PLASMA CONCENTRATION;

ADMINISTRATION, ORAL; ADULT; ANTIFUNGAL AGENTS; AREA UNDER CURVE; CROSS-OVER STUDIES; FEMALE; HUMANS; MALE; MIDDLE AGED; OBESITY; PYRIMIDINES; TRIAZOLES; YOUNG ADULT;

EID: 79956320009     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.01765-10     Document Type: Article

References (16)

1. Andes, D., K. Marchillo, T. Stamstad, and R. Conklin. 2003. In vivo pharmacokinetics and pharmacodynamics of a new triazole, voriconazole, in a murine candidiasis model. Antimicrob. Agents Chemother. 47:3165-3169.
2. Brunner, M., and O. Langer. 2006. Microdialysis versus other techniques for the clinical assessment of in vivo tissue drug distribution. AAPS J. 8:E263-E271.
3. Cockcroft, D. W., and M. H. Gault. 1976. Prediction of creatinine clearance from serum creatinine. Nephron 16:31-41.
4. Damle, B., R. LaBadie, P. Crownover, and P. Glue. 2008. Pharmacokinetic interactions of efavirenz and voriconazole in healthy volunteers. Br. J. Clin. Pharmacol. 65:523-530.
5. Flegal, K. M., M. D. Carroll, C. L. Ogden, and L. R. Curtin. Prevalence and trends in obesity among US adults, 1999-2008. JAMA 303:235-241.
6. Hanley, M. J., D. R. Abernethy, and D. J. Greenblatt. Effect of obesity on the pharmacokinetics of drugs in humans. Clin. Pharmacokinet 49:71-87.
7. Janmahasatian, S., et al. 2005. Quantification of lean bodyweight. Clin. Pharmacokinet. 44:1051-1065.
8. Lewis, R. E. 2008. What is the "therapeutic range" for voriconazole? Clin. Infect. Dis. 46:212-214.
9. Mavridou, E., R. J. Bruggemann, W. J. Melchers, P. E. Verweij, and J. W. Mouton. 2010. Impact of cyp51a mutations on the pharmacokinetic and pharmacodynamic properties of voriconazole in a murine model of disseminated aspergillosis. Antimicrob. Agents Chemother. 54:4758-4764.
10. Mosteller, R. D. 1987. Simplified calculation of body-surface area. N. Engl. J. Med. 317:1098.
11. Pai, M. P. 2010. Estimating the glomerular filtration rate in obese adult patients for drug dosing. Adv. Chronic Kidney Dis. 17:e53-362.
12. Pai, M. P., and D. T. Bearden. 2007. Antimicrobial dosing considerations in obese adult patients. Pharmacotherapy 27:1081-1091.
13. Pai, M. P., and F. P. Paloucek. 2000. The origin of the "ideal" body weight equations. Ann. Pharmacother. 34:1066-1069.
14. Pfizer, Inc. 2010. Vfend® (voriconazole for injection, tablets and for oral suspension) product label. Pfizer, Inc., New York, NY.
15. Purkins, L., et al. 2002. Pharmacokinetics and safety of voriconazole following intravenous- to oral-dose escalation regimens. Antimicrob. Agents Chemother. 46:2546-2553.
16. Theuretzbacher, U., F. Ihle, and H. Derendorf. 2006. Pharmacokinetic/ pharmacodynamic profile of voriconazole. Clin. Pharmacokinet. 45:649-663.